BIIB115

Phase 1Small molecule

Biogen

BIIB115 is one of 27 small molecule programs targeting Spinal Muscular Atrophy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spinal Muscular AtrophyActive, not recruiting

Muscular Atrophy, SpinalActive, not recruiting

Spinal Muscular AtrophyPhase 1

Active, not recruiting

Muscular Atrophy, SpinalPhase 1

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Spinal Muscular Atrophy

#DrugCompanyPhaseTrials

Evrysdi

Roche

Approved

8 2

Spinraza

Biogen

Phase 3

20 3

Prilosec

DDexcel Pharma Technologies Ltd.

Amondys 45

Depakote

2 6

Droxia

TTheravia

Phase 2

3 7

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 8

Rilutek

AAzurity Pharmaceuticals

Phase 2

1 9

Onasemnogene Abeparvovec

Novartis

Phase 3

7 10

RO7204239

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 1Active, not recruiting

Muscular Atrophy, Spinal

NCT05575011

Clinical

Trials by Indication[1]

Muscular Atrophy, Spinal1 trial

A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study With Long-Term Extension in Pediatric SMA Participants Previously Treated With Onasemnogene Abeparvovec (Zolgensma™) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Active, not recruiting· Biogen logo

Biogen·Phase 1·NCT05575011·62 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BIIB115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BIIB115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BIIB115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biogen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Biogen

BIIB115

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Muscular Atrophy, Spinal1 trial

References

Drug Info

Quick Facts

Related News